Meng-Xuan Zuo Meng-Xuan Zuo

Dr. Meng-Xuan Zuo Meng-Xuan Zuo


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2018 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
XHXue Han
Xue Han
YGYang-Kui Gu
Yang-Kui Gu
SLShao-Long Li
Shao-Long Li
HCHao Chen
Hao Chen
MCMin-Shan Chen
Min-Shan Chen
JHJinhua Huang
Jinhua Huang


12 July 2024 in International Journal of Surgery
Verified
Journal Article
Open access
MZMeng-Xuan Zuo Meng-Xuan Zuo
Meng-Xuan Zuo Meng-Xuan Zuo
GZGuanglei Mm Zheng
Guanglei Mm Zheng
YCYuzhe Cao
Yuzhe Cao
HLHailei Lu
Hailei Lu
DLDa Li
Da Li
WFWeijun Fan
Weijun Fan
Objective: To ascertain the therapeutic efficacy and safety of FOLFOX (oxaliplatin, fluorouracil, and leucovorin)-based hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors (TKI) and programmed cell death protein-1 inhibitors (PD-1 inhibitors) (triple therapy), as a first-line treatment in high-risk advanced hepatocellular carcinoma (aHCC with Vp4 portal vein invasion or/and tumor diameter ≥10 cm). Methods: This retrospective multicenter study included 466 high-risk aHCC patients treated with either triple therapy ( n =245) or dual therapy (TKI and PD-1 inhibitors, n =221). The overall survival, progression-free survival, objective response rate, and safety were compared between the two groups. Propensity score matching was performed to reduce bias between the two groups. Results: After propensity score matching (1:1), 194 patients in each group were analyzed. The triple-therapy group showed a longer median overall survival (24.6 vs. 11.9 months; HR=0.43, P <0.001) and a longer median progression-free survival (10.0 vs. 7.7 months; HR=0.68, P =0.002) than the dual-therapy group. The survival rates at 6, 12, and 24 months were 94.2, 71.0, and 50.8% for triple therapy and 75.9, 49.9, and 26.8% for dual therapy. The objective response rate in the triple-therapy group was significantly higher (57.7 vs. 28.9%, P <0.001). In the triple-therapy group, more patients converted to non-high-risk (68.0 vs. 36.6%, P <0.001) and received salvage liver resection or ablation after downstaging conversion (16.5% vs. 9.2%, P =0.033). The grade 3/4 adverse events were 59.2 and 47.4% in the triple-therapy group and dual-therapy group, respectively ( P =0.022). Conclusion: FOLFOX-based hepatic arterial infusion chemotherapy plus TKI and PD-1 inhibitors significantly improve survival prognosis compared with TKI plus PD-1 inhibitors. This is a potential first-line treatment for high-risk aHCC, with a relatively controlled safety profile.

4 June 2024 in International Journal of Surgery
Verified
Journal Article
Open access
HJHanyu Jiang
Hanyu Jiang
MZMeng-Xuan Zuo Meng-Xuan Zuo
Meng-Xuan Zuo Meng-Xuan Zuo
WLWang Li
Wang Li
SZShuiqing Zhuo
Shuiqing Zhuo
PWPeihong Wu
Peihong Wu
CAChao An
Chao An
Background: Surgical resection (SR) following transarterial chemoembolization (TACE)-based downstaging is a promising treatment for unresectable hepatocellular carcinoma (uHCC), and identification of patients at high-risk of postoperative recurrence may assist individualized treatment. Purpose: To develop and externally validate preoperative and postoperative prognostic models integrating multimodal CT and digital subtraction angiography features as well as clinico-therapeutic-pathological features for predicting disease-free survival (DFS) after TACE-based downstaging therapy. Materials and methods: From March 2008 to August 2022, 488 consecutive patients with Barcelona Clinic Liver Cancer (BCLC) A/B uHCC receiving TACE-based downstaging therapy and subsequent SR were included from four tertiary-care hospitals. All CT and digital subtraction angiography images were independently evaluated by two blinded radiologists. In the derivation cohort (n=390), the XGBoost algorithm was used for feature selection, and Cox regression analysis for developing nomograms for DFS (time from downstaging to postoperative recurrence or death). In the external testing cohort (n=98), model performances were compared with five major staging systems. Results: The preoperative nomogram included over three tumors [hazard ratio (HR), 1.42; P=0.003], intratumoral artery (HR, 1.38; P=0.006), TACE combined with tyrosine kinase inhibitor (HR, 0.46; P<0.001) and objective response to downstaging therapy (HR, 1.60; P<0.001); while the postoperative nomogram included over three tumors (HR, 1.43; P=0.013), intratumoral artery (HR, 1.38; P=0.020), TACE combined with tyrosine kinase inhibitor (HR, 0.48; P<0.001), objective response to downstaging therapy (HR, 1.69; P<0.001) and microvascular invasion (HR, 2.20; P<0.001). The testing dataset C-indexes of the preoperative (0.651) and postoperative (0.687) nomograms were higher than all five staging systems (0.472–0.542; all P<0.001). Two prognostically distinct risk strata were identified according to these nomograms (all P<0.001). Conclusion: Based on 488 patients receiving TACE-based downstaging therapy and subsequent SR for BCLC A/B uHCCs, the authors developed and externally validated two nomograms for predicting DFS, with superior performances than five major staging systems and effective survival stratification.

2 July 2025 in International Journal of Surgery
Verified
Journal Article
Open access
CAChao An
Chao An
MZMeng-Xuan Zuo Meng-Xuan Zuo
Meng-Xuan Zuo Meng-Xuan Zuo
WLWang Li
Wang Li
PWPeihong Wu
Peihong Wu
Background: Currently, there is still a lack of noninvasive, automated, and accurate machine-learning (ML) models for prognostic risk stratification of intermediate-stage hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). Purpose: We aimed to develop an ML model for prognostic risk stratification of intermediate-stage HCC after TACE to assist physicians in decision-making. Methods: Between April 2008 and October 2022, consecutive patients with intermediate-stage HCC undergoing initial conventional TACE were retrospectively enrolled from seven tertiary hospitals. A system utilizing natural language processing technology was used to extract clinical information from electronic medical records to develop the ML models. The primary outcomes were 2-year HCC-related death and cancer-related survival (CRS, defined as the interval from initial TACE to either HCC-related death or last follow-up). The ML models’ performance and their comparison with various biomarkers were assessed. Results: A total of 4426 eligible patients were included (3906 males, 520 females; median age, 54 years ± 11 [standard deviation]; 2667 in the training cohort, 667 in the internal test cohort, and 1092 patients in the external test cohort). Six ML models were developed, with the XGBoost model demonstrating the best predictive performance. It achieved an AUC of 0.842 (95% CI, 0.827–0.857) in the training cohort, 0.815 (95% CI, 0.783–0.847) in the internal test cohort, and 0.798 (95% CI, 0.771–0.824) in the external test cohort. Among high-risk patients stratified by the XGBoost model, those who received TACE combined with microwave ablation had significantly higher cumulative CRS rates than those treated with TACE alone. Conclusion: We developed a noninvasive, automated, and accurate ML model, the XGBoost model, with robust performance in prognostic risk stratification for intermediate-stage HCC following TACE.

28 January 2024 in World Journal of Gastroenterology
Verified
Journal Article
Open access
YCYu-Zhe Cao
Yu-Zhe Cao
GZGuang-Lei Zheng
Guang-Lei Zheng
TZTian-Qi Zhang
Tian-Qi Zhang
HSHong-Yan Shao
Hong-Yan Shao
JPJia-Yu Pan
Jia-Yu Pan
MZMeng-Xuan Zuo Meng-Xuan Zuo
Meng-Xuan Zuo Meng-Xuan Zuo
BACKGROUND Hepatic arterial infusion chemotherapy (HAIC) has been proven to be an ideal choice for treating unresectable hepatocellular carcinoma (uHCC). HAIC-based treatment showed great potential for treating uHCC. However, large-scale studies on HAIC-based treatments and meta-analyses of first-line treatments for uHCC are lacking. AIM To investigate better first-line treatment options for uHCC and to assess the safety and efficacy of HAIC combined with angiogenesis inhibitors, programmed cell death of protein 1 (PD-1) and its ligand (PD-L1) blockers (triple therapy) under real-world conditions. METHODS Several electronic databases were searched to identify eligible randomized controlled trials for this meta-analysis. Study-level pooled analyses of hazard ratios (HRs) and odds ratios (ORs) were performed. This was a retrospective single-center study involving 442 patients with uHCC who received triple therapy or angiogenesis inhibitors plus PD-1/PD-L1 blockades (AIPB) at Sun Yat-sen University Cancer Center from January 2018 to April 2023. Propensity score matching (PSM) was performed to balance the bias between the groups. The Kaplan-Meier method and cox regression were used to analyse the survival data, and the log-rank test was used to compare the suvival time between the groups. RESULTS A total of 13 randomized controlled trials were included. HAIC alone and in combination with sorafenib were found to be effective treatments (P values for ORs: HAIC, 0.95; for HRs: HAIC + sorafenib, 0.04). After PSM, 176 HCC patients were included in the analysis. The triple therapy group (n = 88) had a longer median overall survival than the AIPB group (n = 88) (31.6 months vs 14.6 months, P < 0.001) and a greater incidence of adverse events (94.3% vs 75.4%, P < 0.001). CONCLUSION This meta-analysis suggests that HAIC-based treatments are likely to be the best choice for uHCC. Our findings confirm that triple therapy is more effective for uHCC patients than AIPB.